semaglutide cvot trial Summary of the primary end-point results of the six GLP1-RA studied in A Review of Oral Semaglutide

A phase II/III clinical trial (ADAPT-JR) of VYVGART in children and adolescents, defined as individuals between 2 and 18 years of age, with gMG is estimated to be completed within 2024 (NCT04833894)

Memorial Michelangelo Barcella in memory of Michelangelo Barcella and by donations in memory of Daniela Pinto, Alfredo Zanola, Tiziana Tassoni

Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect absorption

This counseling helps manage side effects, optimize weight loss results, preserve muscle mass, and establish sustainable eating habits while on these medications